Giant Scrotal Fibrolipoma.
Thessaloníki, Greece. In Rare Tumors, Jan 2016
On immunohistochemistry, MDM2 and CDK4 were not expressed.
Targeting CDK4 and CDK6: From Discovery to Therapy.
London, United Kingdom. In Cancer Discov, Jan 2016
UNASSIGNED: Biochemical and genetic characterization of D-type cyclins, their cyclin D-dependent kinases (CDK4 and CDK6), and the polypeptide CDK4/6 inhibitor p16(INK4) over two decades ago revealed how mammalian cells regulate entry into the DNA synthetic (S) phase of the cell-division cycle in a retinoblastoma protein-dependent manner.
The history and future of targeting cyclin-dependent kinases in cancer therapy.
Dallas, United States. In Nat Rev Drug Discov, Feb 2015
In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle.
Promising rationally derived combination therapy with PI3K and CDK4/6 inhibitors.
More papers using
Boston, United States. In Cancer Cell, 2014
In this issue of Cancer Cell, Vora and colleagues demonstrate that persistent CDK4 and pRB activation underlie acquired resistance to phosphatidylinositol 3-kinase (PI3K) inhibitors in breast cancer cell lines, suggesting that clinical evaluation of rational combination therapy with PI3K and CDK4/6 inhibitors to mitigate resistance to PI3K inhibition is warranted.
Chlorpromazines and cancer
In Apoptosis, 1971
... study: anti-Akt, anti-phospho-specific Akt, anti-PI3K, anti-phospho-specific PI3K, anti-cyclin A, anti-cyclin B1, anti-cyclin D1, anti-CDK1, anti-CDK2, anti-CDK4 (Santa Cruz Biotechnology, Santa Cruz, CA), anti-caspase-3, ...